S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

enVVeno Medical (NVNO) Competitors

$4.62
-0.16 (-3.35%)
(As of 04/19/2024 ET)

NVNO vs. SEPA, PDEX, XAIR, MGRM, ICCM, SRTS, HSAQ, GBS, NSPR, and CTSO

Should you be buying enVVeno Medical stock or one of its competitors? The main competitors of enVVeno Medical include SEP Acquisition (SEPA), Pro-Dex (PDEX), Beyond Air (XAIR), Monogram Orthopaedics (MGRM), IceCure Medical (ICCM), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), GBS (GBS), InspireMD (NSPR), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.

enVVeno Medical vs.

SEP Acquisition (NASDAQ:SEPA) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.

3.7% of SEP Acquisition shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 20.0% of SEP Acquisition shares are held by company insiders. Comparatively, 17.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SEP Acquisition has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

In the previous week, SEP Acquisition and SEP Acquisition both had 1 articles in the media. SEP Acquisition's average media sentiment score of 0.52 beat enVVeno Medical's score of 0.00 indicating that enVVeno Medical is being referred to more favorably in the news media.

Company Overall Sentiment
SEP Acquisition Neutral
enVVeno Medical Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SEP Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
enVVeno Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SEP AcquisitionN/AN/A$7.71MN/AN/A
enVVeno MedicalN/AN/A-$23.52M-$1.92-2.41

enVVeno Medical's return on equity of 0.00% beat SEP Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
SEP AcquisitionN/A N/A -5.98%
enVVeno Medical N/A -70.17%-64.68%

enVVeno Medical received 156 more outperform votes than SEP Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
SEP AcquisitionN/AN/A
enVVeno MedicalOutperform Votes
156
62.65%
Underperform Votes
93
37.35%

Summary

SEP Acquisition and enVVeno Medical tied by winning 4 of the 8 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVNO vs. The Competition

MetricenVVeno MedicalSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$61.52M$3.63B$4.88B$7.32B
Dividend YieldN/A2.18%2.92%3.97%
P/E Ratio-2.4120.28228.8720.05
Price / SalesN/A55.772,467.3181.89
Price / CashN/A43.1647.6334.38
Price / Book1.334.224.574.15
Net Income-$23.52M$4.44M$104.47M$214.00M
7 Day Performance-7.41%-3.81%-4.52%-3.51%
1 Month Performance-22.61%-8.24%-6.82%-6.05%
1 Year Performance10.00%12.82%6.59%3.98%

enVVeno Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SEPA
SEP Acquisition
0 of 5 stars
$11.58
-1.8%
N/A-17.8%$67.28MN/A0.00N/AGap Down
PDEX
Pro-Dex
0 of 5 stars
$17.82
-1.6%
N/A+18.3%$62.55M$46.09M23.76145News Coverage
XAIR
Beyond Air
2.9506 of 5 stars
$1.67
+3.7%
$11.25
+573.7%
-78.3%$60.19MN/A-0.7898
MGRM
Monogram Orthopaedics
0 of 5 stars
$2.31
-4.5%
N/AN/A$76.55M$364,999.00-2.9228Gap Down
ICCM
IceCure Medical
1.4017 of 5 stars
$1.25
flat
$2.95
+136.0%
-13.9%$57.03M$3.23M-3.7965Analyst Report
SRTS
Sensus Healthcare
2.9078 of 5 stars
$3.45
-3.6%
$7.50
+117.4%
-33.2%$56.55M$24.41M115.0435News Coverage
Positive News
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$4.89
-0.8%
N/A-76.5%$54.83MN/A0.004
GBS
GBS
0 of 5 stars
$3.62
-3.7%
N/A-9.9%$53.90M$440,000.00-6.467
NSPR
InspireMD
2.0224 of 5 stars
$2.28
-2.6%
$4.85
+112.7%
+106.9%$53.48M$6.21M-2.1165Analyst Report
CTSO
Cytosorbents
1.3258 of 5 stars
$0.98
+2.1%
$2.50
+155.1%
-73.9%$52.25M$31.08M-1.53198Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:NVNO) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners